| UHC Commercial Medical & Drug | Immune Globulin (IVIG and SCIG) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Implanted Spinal Drug Delivery Systems – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Natalizumab (Tyruko® & Tysabri®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Office-Based Procedures – Site of Service – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Panniculectomy Surgery – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Pharmacogenetic Panel Testing – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Preventive Care Services – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Provider Administered Drugs – Preferred Products – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |